Karina Pereira Gomes

Dr. Karina Pereira Gomes

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
KGKarina Pereira Gomes
Karina Pereira Gomes
JKJacob Korodimas
Jacob Korodimas
ELEmily Liu
Emily Liu
NPNirav Patel
Nirav Patel
XYXiaoyan Yang
Xiaoyan Yang
SGSpencer Gibson
Spencer Gibson
Lymphedema is a chronic lymphatic disorder characterized by persistent tissue swelling, pain, and recurrent infections, often secondary to cancer treatment, surgery, or obesity. Obesity-associated increases in saturated fatty acids (SFAs) have been linked to lipotoxicity. In this study, patients with secondary lymphedema showed a significantly lower plasma polyunsaturated to saturated fatty acid (PUFA/SFA) ratio compared to BMI-matched controls. Stearic acid, a common dietary SFA, induced apoptosis, oxidative stress, and endoplasmic reticulum (ER) stress in human lymphatic endothelial cells. In a mouse model, a short-term high-SFA diet was used to lower the plasma PUFA/SFA ratio, which worsened tail swelling, oxidative stress, ER stress, and tissue damage following lymphatic injury. Switching to a standard chow diet after surgery prevented these effects. Patients with lymphedema also exhibited elevated levels of fatty acid-binding protein 4 (FABP4), a lipid chaperone associated with metabolic stress. FABP4 inhibition reduced stearic acid-induced cell death in vitro and mitigated tissue damage in vivo. These findings suggest a pathogenic role for SFAs and support dietary modulation and FABP4 inhibition as potential therapeutic strategies for lymphedema.

Verified
Journal Article
Open access
PDF file
LHLazina Hossain
Lazina Hossain
KGKarina Pereira Gomes
Karina Pereira Gomes
YYYan Yang
Yan Yang
ELEmily Liu
Emily Liu
JTJacques Du Toit
Jacques Du Toit
SGSpencer Gibson
Spencer Gibson
Secondary lymphedema is caused by damage to the lymphatic system from surgery, cancer treatment, infection, trauma, or obesity. This damage induces stresses such as oxidative stress and hypoxia in lymphatic tissue, impairing the lymphatic system. In response to damage, vascular endothelial growth factor C (VEGF-C) levels increase to induce lymphangiogenesis. Unfortunately, VEGF-C often fails to repair the lymphatic damage in lymphedema. The underlying mechanism contributing to lymphedema is not well understood. In this study, we found that surgery-induced tail lymphedema in a mouse model increased oxidative damage and cell death over 16 days. This corresponded with increased VEGF-C levels in mouse tail lymphedema tissue associated with macrophage infiltration. Similarly, in the plasma of patients with secondary lymphedema, we found a positive correlation between VEGF-C levels and redox imbalance. To determine the effect of oxidative stress in the presence or absence of VEGF-C, we found that hydrogen peroxide (H2O2) induced cell death in human dermal lymphatic endothelial cells (HDLECs), which was potentiated by VEGF-C. The cell death induced by VEGF-C and H2O2 in HDLECs was accompanied by increased reactive oxygen species (ROS) levels and a loss of mitochondrial membrane potential. Antioxidant pre-treatment rescued HDLECs from VEGF-C-induced cell death and decreased ROS under oxidative stress. As expected, VEGF-C increased the number of viable and proliferating HDLECs. However, upon H2O2 treatment, VEGF-C failed to increase either viable or proliferating cells. Since oxidative stress leads to DNA damage, we also determined whether VEGF-C treatment induces DNA damage in HDLECs undergoing oxidative stress. Indeed, DNA damage, detected in the form of gamma H2AX (γH2AX), was increased by VEGF-C under oxidative stress. The potentiation of oxidative stress damage induced by VEFG-C in HDLECs was associated with p53 activation. Finally, the inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3) activation blocked VEGF-C-induced cell death following H2O2 treatment. These results indicate that VEGF-C further sensitizes lymphatic endothelial cells to oxidative stress by increasing ROS and DNA damage, potentially compromising lymphangiogenesis.

3 September 2020 in Clinical Science
Verified
Journal Article
Open access
PDF file
KGKarina Pereira Gomes
Karina Pereira Gomes
PBPedro Paulo Pereira Braga
Pedro Paulo Pereira Braga
CLClaudio Quintino de Lima
Claudio Quintino de Lima
PGPoliana Peres Ghazale
Poliana Peres Ghazale
Gustavo Rodrigues PedrinoGustavo Rodrigues Pedrino
Gustavo Rodrigues Pedrino
DCDiego Basile Colugnati
Diego Basile Colugnati
Temporal lobe epilepsy (TLE) is the most frequent type of epilepsy and is often refractory to pharmacological treatment. In this scenario, extensive research has identified components of the renin–angiotensin system (RAS) as potential therapeutic targets. Therefore, the aim of the present study was to evaluate the effects of long-term treatment with angiotensin-(1-7) [Ang-(1-7)] in male Wistar rats with TLE induced by pilocarpine (PILO). Rats with TLE were submitted to intracerebroventricular (icv) infusion of Ang-(1-7) (200 ng/kg/h) for 28 days, starting at the first spontaneous motor seizure (SMS). Body weight, food intake, and SMS were evaluated daily. Behavioral tests and hippocampal protein levels were also evaluated at the end of the treatment. Ang-(1-7) treatment reduced the frequency of SMS and attenuated low anxiety levels, increased locomotion/exploration, and reduced body weight gain that was induced by TLE. Moreover, Ang-(1-7) positively regulated the hippocampal levels of antioxidant protein catalase and antiapoptotic protein B-cell lymphoma 2 (Bcl-2), as well as mammalian target of rapamycin (mTOR) phosphorylation, which were reduced by TLE. The hippocampal up-regulation of angiotensin type 1 receptor induced by TLE was also attenuated by Ang-(1-7), while the Mas receptor (MasR) was down-regulated compared with epilepsy. These data show that Ang-(1-7) presents an antiepileptic effect, increasing neuroprotection markers and reducing SMS frequency, body weight, and behavior impairments found in TLE. Therefore, Ang-(1-7) is a promising coadjutant therapeutic option for the treatment of TLE.

14 May 2021 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KGKarina Pereira Gomes
Karina Pereira Gomes
LALuiz G. de Almeida
Luiz G. de Almeida
NBNoura Ballasy
Noura Ballasy
PEPariya Edalat
Pariya Edalat
DYDaniel Young
Daniel Young
VPVaibhav B. Patel
Vaibhav B. Patel
Diabetic cardiomyopathy (DCM) occurs independently of coronary artery disease or hypertension, often leading to heart failure and death. Although remarkable progress has been made in recent years, there is still no specific therapy for myocardial damage induced by DCM, mainly due to its unclear molecular basis. To elucidate the molecular mechanisms involved in the DCM progress, we have performed advanced proteomic profiling analysis of heart tissue samples from the membrane‐bound leptin receptor deficient ( db/db ) mice, a widely used murine model of type 2 diabetes. As previously shown by our research group, db/db mice exhibit clinically relevant DCM phenotype by 6 months of age that includes diastolic dysfunction, cardiac hypertrophy, and cardiac fibrosis. Six‐month‐old C57BL/6J‐lepr/lepr ( db/db ) and C57BL/6J (wild type [WT]) male mice were euthanized, and the left ventricle (LV) was appropriately collected and processed for proteomic analysis. By shotgun proteomics performed after dimethyl labelling, we identified 77 differentially expressed proteins in LV of db/db mice. Among these, 27 proteins were downregulated in response to chronic diabetes, while 50 were upregulated. Many of these proteins were associated with energy metabolism, cytoskeleton organization, and calcium handling. The peptide levels of subunits alpha, beta and delta of ATP synthase were upregulated in the LVs of db/db mice. These subunits are arranged to form the F1 domain, a catalytic assembly of the enzyme. We also found a marked induction of cytochrome c1 in db/db mice, which is a catalytic core subunit of the complex III, responsible for electron transfer to cytochrome c. We propose that this may represent an adaptive mechanism by which the diabetic heart attempts to increase electron transfer and thereby enhance mitochondrial ATP production. Conversely, in db/db mice we found a decrease in peptide levels of NADH dehydrogenase 1 beta subcomplex subunit 11, a subunit of complex I that catalyzes transfer of electrons to ubiquinone. In diabetic hearts, we also found a downregulation of atypical kinase COQ8A, an essential lipid‐soluble electron transporter involved in the biosynthesis of ubiquinone. These data suggest that despite attempts by hearts from the diabetic mice to augment mitochondrial ATP production, decreased levels of key components of the electron transport chain may contribute to impaired mitochondrial ATP production. It is likely that ATP synthase subunits and cytochrome c1 may also be downregulated with prolonged persistence of the diabetic phenotype. Our study suggests that diabetic hearts displayed altered expression of mitochondrial metabolic peptides, which may contribute to the progression of DCM in db/db mice.

23 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SGSpencer Gibson
Spencer Gibson
LHLazina Hossain
Lazina Hossain
KGKarina Pereira Gomes
Karina Pereira Gomes
JTJacques Du Toit
Jacques Du Toit
XYXiaoyan Yang
Xiaoyan Yang
NBNikki Boerkamp
Nikki Boerkamp
Lymphedema is a chronic, progressive disorder of the lymphatic system, characterized by tissue swelling due to abnormal accumulation of interstitial fluid and progressive tissue remodeling. It most commonly arises as a secondary complication to cancer treatment, surgical intervention, and obesity. Lymphedema tissue is hypoxic and characterized by elevated levels of hypoxia-inducible factor-1α (HIF-1α). Hypoxia stimulation increases the expression of the fatty acid-binding protein FABP4. FABP4 is expressed in lymphatic endothelial cells, but its role under hypoxic conditions has not yet been investigated. Our study shows that hypoxia upregulated FABP4 expression in human dermal lymphatic endothelial cells (HDLECs). Pretreatment with a saturated fatty acid, stearic acid (SA), sensitizes HDLECs to hypoxia-induced cell death. During hypoxia, SA-induced lipotoxicity includes increased generation of reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress. This led to apoptosis and autophagy-mediated cell death in HDLECs. Finally, targeting FABP4, the key mediator in lipotoxicity, attenuated HDLECs' death by reducing ROS generation and ER stress. In addition, the oral administration of the FABP4 inhibitor in the lymphedema mouse tail model also showed reduced lymphatic cell death in lymphedema tissue. Thus, these observations identify FABP4 as a potential therapeutic target in the hypoxic lymphedema microenvironment by elucidating its mechanistic role in lipotoxicity.

10 June 2026 in Cell Death & Disease
Verified
Journal Article
Open access
SSSamaneh Safarpour
Samaneh Safarpour
KGKarina Pereira Gomes
Karina Pereira Gomes
JKJacob Korodimas
Jacob Korodimas
MVMilica Vignjevic
Milica Vignjevic
MMMadhumita S. Manivannan
Madhumita S. Manivannan
SGSpencer Gibson
Spencer Gibson
Cancer-related lymphedema (CRL) is an incurable disease characterized by progressive swelling of extremities. One of the risk factors in developing CRL is cancer treatments, including surgery and radiation. This leads to damage to the lymphatic system, causing accumulation of interstitial fluid, infiltration of inflammatory cells and cytokine release, tissue remodeling, accumulation of subcutaneous fat, and fibrosis. Radiation therapy (RT) inhibits lymphatic proliferation and survival by downregulating vascular endothelial growth factor receptor 3 (VEGFR-3) in lymphatic endothelial cells (LECs). How radiation affects CRL progression remains unclear. In this study, we found that RT reduced LEC growth and increased senescence in LECs as determined by increased senescence-associated β-galactosidase (SA-βgal) activity and increased protein expression of senescence markers p53, p21, and p16. Using the mouse tail lymphedema model, we found that tail swelling was increased after RT in both sham control and lymphatic ablation mice. After 30 days, tail swelling was maintained in RT treated mice with lymphatic ablation, whereas RT treated sham controls showed reduced swelling. This corresponded to an increase in senescent cells and apoptosis after RT in lymphatic-ablated mice compared to sham controls. We also found increased levels of senescence-related cytokines and chemokines in lymphedema patients’ plasma samples who had RT compared to surgery alone or non-lymphedema controls. Finally, we found that RT increased anti-apoptotic protein BCL-2 in human LECs and lymphatic ablated mouse tissue. Treatment with the senolytic agent venetoclax (VCX), a BCL-2 inhibitor, selectively killed RT-induced senescent LECs and reduced swelling in the RT-induced tail lymphedema model. This suggests that RT contributes to CRL, at least in part, by inducing cellular senescence.